Stockwatch: Coronavirus Takes A Bite Out Of AstraZeneca’s Guidance, GSK and AbbVie Get Spinning
With Great Potential For Emerging Market Sales Comes Great Volatility
Executive Summary
The Coronavirus outbreak makes its first dent into pharma's 2020 prospects as AstraZeneca admits possible impact, while could AbbVie's aesthetic plans raise the prospect of another GSK-style spin off?
You may also be interested in...
AstraZeneca Returns To Growth, But Coronavirus Likely To Hit China Revenues
With a long turnaround process now complete, AstraZeneca could hit double digit growth in 2020, thanks to existing products and new approvals such as roxadustat.
Countdown To The Allergan Merger, And More From AbbVie’s Q4 Earnings
Despite Humira’s ex-US sales erosion, AbbVie reports strong launches for Skyrizi and Rinvoq, continued growth for hematological oncology franchise, and boasts it has a thriving R&D engine.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.